Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
963 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Gastric Cancer - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer - Pipeline Review, H2 2016, provides an overview of the Gastric Cancer (Oncology) pipeline landscape. Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastric Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 15, 68, 68, 7, 65, 6 and 2 respectively for Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 5, 3, 7 and 1 molecules, respectively for Gastric Cancer. Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology). - The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 9 Gastric Cancer Overview 10 Therapeutics Development 11 Gastric Cancer - Therapeutics under Development by Companies 13 Gastric Cancer - Therapeutics under Investigation by Universities/Institutes 24 Gastric Cancer - Pipeline Products Glance 25 Gastric Cancer - Products under Development by Companies 29 Gastric Cancer - Products under Investigation by Universities/Institutes 45 Gastric Cancer - Companies Involved in Therapeutics Development 46 Gastric Cancer - Therapeutics Assessment 184 Drug Profiles 214 Gastric Cancer - Dormant Projects 911 Gastric Cancer - Discontinued Products 924 Gastric Cancer - Product Development Milestones 928 Appendix 935
List of Tables
Number of Products under Development for Gastric Cancer, H2 2016 38 Number of Products under Development for Gastric Cancer - Comparative Analysis, H2 2016 39 Number of Products under Development by Companies, H2 2016 40 Number of Products under Development by Companies, H2 2016 (Contd..1) 41 Number of Products under Development by Companies, H2 2016 (Contd..2) 42 Number of Products under Development by Companies, H2 2016 (Contd..3) 43 Number of Products under Development by Companies, H2 2016 (Contd..4) 44 Number of Products under Development by Companies, H2 2016 (Contd..5) 45 Number of Products under Development by Companies, H2 2016 (Contd..6) 46 Number of Products under Development by Companies, H2 2016 (Contd..7) 47 Number of Products under Development by Companies, H2 2016 (Contd..8) 48 Number of Products under Development by Companies, H2 2016 (Contd..9) 49 Number of Products under Development by Companies, H2 2016 (Contd..10) 50 Number of Products under Investigation by Universities/Institutes, H2 2016 51 Comparative Analysis by Late Stage Development, H2 2016 52 Comparative Analysis by Clinical Stage Development, H2 2016 53 Comparative Analysis by Early Stage Development, H2 2016 54 Comparative Analysis by Unknown Stage Development, H2 2016 55 Products under Development by Companies, H2 2016 56 Products under Development by Companies, H2 2016 (Contd..1) 57 Products under Development by Companies, H2 2016 (Contd..2) 58 Products under Development by Companies, H2 2016 (Contd..3) 59 Products under Development by Companies, H2 2016 (Contd..4) 60 Products under Development by Companies, H2 2016 (Contd..5) 61 Products under Development by Companies, H2 2016 (Contd..6) 62 Products under Development by Companies, H2 2016 (Contd..7) 63 Products under Development by Companies, H2 2016 (Contd..8) 64 Products under Development by Companies, H2 2016 (Contd..9) 65 Products under Development by Companies, H2 2016 (Contd..10) 66 Products under Development by Companies, H2 2016 (Contd..11) 67 Products under Development by Companies, H2 2016 (Contd..12) 68 Products under Development by Companies, H2 2016 (Contd..13) 69 Products under Development by Companies, H2 2016 (Contd..14) 70 Products under Development by Companies, H2 2016 (Contd..15) 71 Products under Investigation by Universities/Institutes, H2 2016 72 Gastric Cancer - Pipeline by 3SBio Inc., H2 2016 73 Gastric Cancer - Pipeline by AB Science SA, H2 2016 74 Gastric Cancer - Pipeline by AbbVie Inc, H2 2016 75 Gastric Cancer - Pipeline by AbGenomics International, Inc., H2 2016 76 Gastric Cancer - Pipeline by ADC Therapeutics Sarl, H2 2016 77 Gastric Cancer - Pipeline by Advaxis, Inc., H2 2016 78 Gastric Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2016 79 Gastric Cancer - Pipeline by Agenus, Inc., H2 2016 80 Gastric Cancer - Pipeline by Almac Discovery Limited, H2 2016 81 Gastric Cancer - Pipeline by Alteogen Inc., H2 2016 82 Gastric Cancer - Pipeline by Ambrx, Inc., H2 2016 83 Gastric Cancer - Pipeline by Amgen Inc., H2 2016 84 Gastric Cancer - Pipeline by arGEN-X BV, H2 2016 85 Gastric Cancer - Pipeline by Asana BioSciences, LLC, H2 2016 86 Gastric Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2016 87 Gastric Cancer - Pipeline by Astellas Pharma Inc., H2 2016 88 Gastric Cancer - Pipeline by AstraZeneca Plc, H2 2016 89 Gastric Cancer - Pipeline by Atara Biotherapeutics, Inc., H2 2016 90 Gastric Cancer - Pipeline by Athenex, Inc., H2 2016 91 Gastric Cancer - Pipeline by Azaya Therapeutics, Inc., H2 2016 92 Gastric Cancer - Pipeline by Basilea Pharmaceutica Ltd., H2 2016 93 Gastric Cancer - Pipeline by Bayer AG, H2 2016 94 Gastric Cancer - Pipeline by BeiGene, Ltd., H2 2016 95 Gastric Cancer - Pipeline by Betta Pharmaceuticals Co. Ltd., H2 2016 96 Gastric Cancer - Pipeline by Bionovis SA, H2 2016 97 Gastric Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 98 Gastric Cancer - Pipeline by Boston Biomedical, Inc., H2 2016 99 Gastric Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 100 Gastric Cancer - Pipeline by Calithera Biosciences, Inc., H2 2016 101 Gastric Cancer - Pipeline by Cancer Prevention Pharmaceuticals, Inc., H2 2016 102 Gastric Cancer - Pipeline by Celgene Corporation, H2 2016 103 Gastric Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2016 104 Gastric Cancer - Pipeline by Cellectar Biosciences, Inc., H2 2016 105 Gastric Cancer - Pipeline by Celltrion, Inc., H2 2016 106 Gastric Cancer - Pipeline by Celon Pharma Sp. z o.o., H2 2016 107 Gastric Cancer - Pipeline by Cerulean Pharma, Inc., H2 2016 108 Gastric Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2016 109 Gastric Cancer - Pipeline by Curaxys, S.L., H2 2016 110 Gastric Cancer - Pipeline by DAE HWA Pharmaceutical Co., Ltd., H2 2016 111 Gastric Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 112 Gastric Cancer - Pipeline by Debiopharm International SA , H2 2016 113 Gastric Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2016 114 Gastric Cancer - Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016 115 Gastric Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016 116 Gastric Cancer - Pipeline by Eddingpharm, H2 2016 117 Gastric Cancer - Pipeline by EirGenix Inc., H2 2016 118 Gastric Cancer - Pipeline by Eli Lilly and Company, H2 2016 119 Gastric Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2016 120 Gastric Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 121 Gastric Cancer - Pipeline by Five Prime Therapeutics, Inc., H2 2016 122 Gastric Cancer - Pipeline by Frost Biologic, Inc., H2 2016 123 Gastric Cancer - Pipeline by Galena Biopharma, Inc., H2 2016 124 Gastric Cancer - Pipeline by Genelux Corporation, H2 2016 125 Gastric Cancer - Pipeline by Genentech, Inc., H2 2016 126 Gastric Cancer - Pipeline by Gilead Sciences, Inc., H2 2016 127 Gastric Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 128 Gastric Cancer - Pipeline by GlycoNex Inc., H2 2016 129 Gastric Cancer - Pipeline by Glycotope GmbH, H2 2016 130 Gastric Cancer - Pipeline by Green Cross Corporation, H2 2016 131 Gastric Cancer - Pipeline by Halozyme Therapeutics, Inc., H2 2016 132 Gastric Cancer - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 133 Gastric Cancer - Pipeline by Horizon Pharma Plc, H2 2016 134 Gastric Cancer - Pipeline by Hutchison MediPharma Limited, H2 2016 135 Gastric Cancer - Pipeline by Ignyta, Inc., H2 2016 136 Gastric Cancer - Pipeline by Immunomedics, Inc., H2 2016 137 Gastric Cancer - Pipeline by Imugene Limited, H2 2016 138 Gastric Cancer - Pipeline by Incyte Corporation, H2 2016 139 Gastric Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 140 Gastric Cancer - Pipeline by INSYS Therapeutics, Inc., H2 2016 141 Gastric Cancer - Pipeline by Intezyne Technologies, Inc., H2 2016 142 Gastric Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 143 Gastric Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H2 2016 144 Gastric Cancer - Pipeline by Johnson & Johnson, H2 2016 145 Gastric Cancer - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2016 146 Gastric Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 147 Gastric Cancer - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016 148 Gastric Cancer - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H2 2016 149 Gastric Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016 150 Gastric Cancer - Pipeline by LegoChem Biosciences, Inc, H2 2016 151 Gastric Cancer - Pipeline by Les Laboratoires Servier SAS, H2 2016 152 Gastric Cancer - Pipeline by MacroGenics, Inc., H2 2016 153 Gastric Cancer - Pipeline by MaxiVAX SA, H2 2016 154 Gastric Cancer - Pipeline by Mebiopharm Co., Ltd., H2 2016 155 Gastric Cancer - Pipeline by MedImmune, LLC, H2 2016 156 Gastric Cancer - Pipeline by Medivation, Inc., H2 2016 157 Gastric Cancer - Pipeline by Merck & Co., Inc., H2 2016 158 Gastric Cancer - Pipeline by Merck KGaA, H2 2016 159 Gastric Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016 160 Gastric Cancer - Pipeline by Mersana Therapeutics, Inc., H2 2016 161 Gastric Cancer - Pipeline by Merus NV, H2 2016 162 Gastric Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 163 Gastric Cancer - Pipeline by Mirna Therapeutics, Inc., H2 2016 164 Gastric Cancer - Pipeline by Molecular Targeting Technologies, Inc., H2 2016 165 Gastric Cancer - Pipeline by MolMed S.p.A., H2 2016 166 Gastric Cancer - Pipeline by NanoCarrier Co., Ltd., H2 2016 167 Gastric Cancer - Pipeline by NeuClone Pty Ltd, H2 2016 168 Gastric Cancer - Pipeline by Novartis AG, H2 2016 169 Gastric Cancer - Pipeline by OBI Pharma, Inc., H2 2016 170 Gastric Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2016 171 Gastric Cancer - Pipeline by Oncobiologics, Inc., H2 2016 172 Gastric Cancer - Pipeline by Oncolys BioPharma Inc, H2 2016 173 Gastric Cancer - Pipeline by Oncolytics Biotech Inc., H2 2016 174 Gastric Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016 175 Gastric Cancer - Pipeline by OncoTherapy Science, Inc., H2 2016 176 Gastric Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 177 Gastric Cancer - Pipeline by Opsona Therapeutics Limited, H2 2016 178 Gastric Cancer - Pipeline by Panacea Biotec Limited, H2 2016 179 Gastric Cancer - Pipeline by Patrys Limited, H2 2016 180 Gastric Cancer - Pipeline by Pfizer Inc., H2 2016 181 Gastric Cancer - Pipeline by Pharma Mar, S.A., H2 2016 182 Gastric Cancer - Pipeline by Puma Biotechnology, Inc., H2 2016 183 Gastric Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2016 184 Gastric Cancer - Pipeline by Rgenix, Inc., H2 2016 185 Gastric Cancer - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016 186 Gastric Cancer - Pipeline by Richter Gedeon Nyrt., H2 2016 187 Gastric Cancer - Pipeline by Samumed LLC, H2 2016 188 Gastric Cancer - Pipeline by Sanofi, H2 2016 189 Gastric Cancer - Pipeline by Sequella, Inc., H2 2016 190 Gastric Cancer - Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2016 191 Gastric Cancer - Pipeline by Shionogi & Co., Ltd., H2 2016 192 Gastric Cancer - Pipeline by Simcere Pharmaceutical Group, H2 2016 193 Gastric Cancer - Pipeline by Sorrento Therapeutics, Inc., H2 2016 194 Gastric Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016 195 Gastric Cancer - Pipeline by Supratek Pharma Inc., H2 2016 196 Gastric Cancer - Pipeline by SynCore Biotechnology Co., Ltd., H2 2016 197 Gastric Cancer - Pipeline by Synovo GmbH, H2 2016 198 Gastric Cancer - Pipeline by Synthon Holdings BV, H2 2016 199 Gastric Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016 200 Gastric Cancer - Pipeline by Taiwan Liposome Company, Ltd., H2 2016 201 Gastric Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 202 Gastric Cancer - Pipeline by Takis S.r.l., H2 2016 203 Gastric Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 204 Gastric Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H2 2016 205 Gastric Cancer - Pipeline by Transgene SA, H2 2016 206 Gastric Cancer - Pipeline by United BioPharma, Inc., H2 2016 207 Gastric Cancer - Pipeline by Vaxon Biotech, H2 2016 208 Gastric Cancer - Pipeline by XuanZhu Pharma Co., Ltd., H2 2016 209 Gastric Cancer - Pipeline by Zymeworks Inc., H2 2016 210 Assessment by Monotherapy Products, H2 2016 211 Assessment by Combination Products, H2 2016 212 Number of Products by Stage and Target, H2 2016 214 Number of Products by Stage and Mechanism of Action, H2 2016 226 Number of Products by Stage and Route of Administration, H2 2016 238 Number of Products by Stage and Molecule Type, H2 2016 240 Gastric Cancer - Dormant Projects, H2 2016 938 Gastric Cancer - Dormant Projects (Contd..1), H2 2016 939 Gastric Cancer - Dormant Projects (Contd..2), H2 2016 940 Gastric Cancer - Dormant Projects (Contd..3), H2 2016 941 Gastric Cancer - Dormant Projects (Contd..4), H2 2016 942 Gastric Cancer - Dormant Projects (Contd..5), H2 2016 943 Gastric Cancer - Dormant Projects (Contd..6), H2 2016 944 Gastric Cancer - Dormant Projects (Contd..7), H2 2016 945 Gastric Cancer - Dormant Projects (Contd..8), H2 2016 946 Gastric Cancer - Dormant Projects (Contd..9), H2 2016 947 Gastric Cancer - Dormant Projects (Contd..10), H2 2016 948 Gastric Cancer - Dormant Projects (Contd..11), H2 2016 949 Gastric Cancer - Dormant Projects (Contd..12), H2 2016 950 Gastric Cancer - Discontinued Products, H2 2016 951 Gastric Cancer - Discontinued Products (Contd..1), H2 2016 952 Gastric Cancer - Discontinued Products (Contd..2), H2 2016 953 Gastric Cancer - Discontinued Products (Contd..3), H2 2016 954
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
